The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by sequential use of nilotinib and imatinib: A GIMEMA protocol LAL 1408.
Cristina Papayannidis
No relevant relationships to disclose
Alfonso Piciocchi
No relevant relationships to disclose
Antonella Vitale
No relevant relationships to disclose
Ilaria Iacobucci
No relevant relationships to disclose
Simona Soverini
No relevant relationships to disclose
Francesco Di Raimondo
No relevant relationships to disclose
Stefania Paolini
No relevant relationships to disclose
Giovanni Pizzolo
No relevant relationships to disclose
Angelo Michele Carella
No relevant relationships to disclose
Mario Cazzola
No relevant relationships to disclose
Antonio Cuneo
No relevant relationships to disclose
Pietro Leoni
No relevant relationships to disclose
Mario Luppi
No relevant relationships to disclose
Enrica Morra
No relevant relationships to disclose
Giorgina Specchia
No relevant relationships to disclose
Loredana Elia
No relevant relationships to disclose
Robin Foa
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Michele Baccarani
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis
Honoraria - Novartis
Giovanni Martinelli
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer; Roche